Literature DB >> 18035959

Prevention of Type 2 diabetes: fact or fiction?

Jean-Louis Chiasson1.   

Abstract

The growing prevalence of Type 2 diabetes with its high morbidity and excess mortality is imposing a heavy burden on healthcare systems. Because of the magnitude of the problem, obviating diabetes has been a long-standing dream. In the last decade, a number of intervention strategies have been shown to be effective for the prevention of diabetes in high-risk populations with prediabetes. Seven studies have now confirmed that lifestyle modifications, including weight-reducing diets and exercise programs, are very effective in precluding or delaying Type 2 diabetes in high-risk populations with impaired glucose tolerance (IGT). Two major trials are the Diabetes Prevention Study (n = 522) from Finland and the Diabetes Prevention Program (n = 3234) from the US. Both studies have shown that intensive lifestyle intervention could reduce the progression of IGT to diabetes by 58%. Furthermore, four currently-available drugs have been established as being effective in preventing diabetes in subjects with prediabetes. The Diabetes Prevention Program revealed that metformin 850 mg b.i.d. reduced the risk of diabetes by 31%. The STOP-NIDDM (Study To Prevent Non-Insulin-Dependent Diabetes Mellitus) trial (n = 1429) showed that acarbose 100 mg t.i.d. with meals decreased the incidence of diabetes by 36% when the diagnosis was based on 2 oral glucose tolerance tests. The XENDOS (Xenical in the Prevention of Diabetes in Obese Subjects) study examined the use of orlistat, an antiobesity drug, as an adjunct to an intensive lifestyle modification program in obese non-diabetic subjects. Orlistat treatment resulted in a 37% decline in the development of diabetes. More recently, the DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) study (n = 5269) demonstrated that rosiglitazone at 8 mg once/day in subjects with prediabetes (IGT and/or impaired fasting glucose) was effective in reducing the risk of diabetes by 60%. It can be concluded that Type 2 diabetes can be prevented or delayed through lifestyle modifications and/or pharmacologic interventions. This is a fact.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18035959     DOI: 10.1517/14656566.8.18.3147

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  11 in total

1.  Personalized medicine for diabetes.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2008-05

Review 2.  Incretin therapy--present and future.

Authors:  Alan J Garber
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 3.  Prediabetes as a therapeutic target.

Authors:  Omid Rad Pour; Samuel Dagogo-Jack
Journal:  Clin Chem       Date:  2010-11-09       Impact factor: 8.327

4.  Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS).

Authors:  J Lindström; M Peltonen; J G Eriksson; P Ilanne-Parikka; S Aunola; S Keinänen-Kiukaanniemi; M Uusitupa; J Tuomilehto
Journal:  Diabetologia       Date:  2012-10-24       Impact factor: 10.122

5.  Antidiabetic action of bezafibrate in a large observational database.

Authors:  James H Flory; Susan Ellenberg; Philippe O Szapary; Brian L Strom; Sean Hennessy
Journal:  Diabetes Care       Date:  2009-01-08       Impact factor: 17.152

6.  Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study.

Authors:  Poobalan Naidoo; Jeffrey Wing; Virendra Rambiritch
Journal:  JMIR Res Protoc       Date:  2016-08-04

7.  Perceived Changes in General Well-being: Findings from the 'MOVEdiabetes' Physical Activity Randomized Control Trial.

Authors:  Thamra S Al-Ghafri; Saud M Al-Harthi; Yahya Al-Farsi; Angela M Craigie; Elaine Bannerman; Annie S Anderson
Journal:  Oman Med J       Date:  2020-07-20

Review 8.  Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapy.

Authors:  Alan J Garber
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

9.  Knowledge and perceptions of diabetes in a semi-urban Omani population.

Authors:  Mohammed A Al Shafaee; Sulaiman Al-Shukaili; Syed Gauher A Rizvi; Yahya Al Farsi; Mushtaq A Khan; Shyam S Ganguly; Mustafa Afifi; Samir Al Adawi
Journal:  BMC Public Health       Date:  2008-07-22       Impact factor: 3.295

Review 10.  Hemoglobin A1c: past, present and future.

Authors:  Saleh A Aldasouqi; Ved V Gossain
Journal:  Ann Saudi Med       Date:  2008 Nov-Dec       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.